The present scoping review provides evidence for the application of leech therapy in the treatment of plastic and reconstructive surgery, musculoskeletal diseases, osteoarthritis, etc..
The first recorded report of the use of leeches is in a medical poem, Alexipharma, for Nicander of Colophon, born 200 B.C.. There is also evidence of the using leeches by large scholars such as Avicenna in The Canon of Medicine and Abd-el-Latif al-Baghdadi in Al-Mukhtarat fi al-Tibb. Barbers-surgeons in the middle ages used to use leeches to shed blood for treating some kind of diseases. With the development of modern medicine, the first use of medical leeches occurred in the 1960's, for intravenous congestion after reconstructive surgery. In 2004 the FDA approved leech therapy to accelerate tissue transplantation.
After the developments of modern medicine, leeches were not used as before, but in the late nineteenth century, leeches were still being used in many countries around the world. Until now, leeches have been used to treat a wide range of diseases. The present study, is a scoping review of the evidence of the indication of leech therapy. The results of this study are based on English articles and dissertations published in databases from 2000 up to July 10, 2017. The results showed that leech therapy could be used in different conditions including venous congestion in plastic and reconstructive surgery, osteoarthritis, cardiovascular diseases due to blood coagulation disorders, migraine headache, skin disorders, diabetic foot ulcers, macroglossia, priapism, cancer complications, and wounds. More researches are needed in wider areas with more precise methodologies to ensure the potential therapeutic effects of leech therapy.
This review summarizes the advances in research on cucurbitacins B, D, E, and I in inducing tumor cell apoptosis, cytoskeletal destruction, cell cycle arrest, and autophagy and in regulating various cancer-related signaling pathways.
Cucurbitacins are present in some traditional Chinese herbs (TCH) such as Gualou (Fructus Trichosanthis),Tianhuafen (Radix Trichosanthis), and Tianguadi (Pedicellus Melo). An ancient book named Shennong Bencao Jing (1602 A.D., Donghan Dynasty of China) has reported that TCH Tianguadi (Pedicellus Melo) and the dried fruit stalk of Cucumis melo L. have been used for treating jaundice because components present in these herbs induce vomiting and aid in expelling phlegm.
Cucurbitacins are highly oxidized tetracyclic triterpenoids that are widely found in plants belonging to Cucurbitaceae family and exert various pharmacological effects. Many cucurbitacin derivatives are available, of which cucurbitacins B, D, E, and I are important members of the cucurbitacin family and exert anticancer effects against various cancers. This review summarizes the advances in research on cucurbitacins B, D, E, and I in inducing tumor cell apoptosis, cytoskeletal destruction, cell cycle arrest, and autophagy and in regulating various cancer-related signaling pathways. In addition, this review summarizes the latest research on the synergistic effects of the combination of cucurbitacins and clinically approved chemotherapeutic drugs. The findings summarized in this review suggest that cucurbitacins are multi-targeting and multi-functional anticancer drugs and that their complex anticancer mechanisms should be examined in future studies. Because of their proven benefits, cucurbitacins have the potential to be used as anticancer drugs in the clinical setting.
This review covers the research progress during 2018 for pharmacological studies on traditional medicine and active natural products. The pharmacological reports on traditional medicine against cancers and diabetes were still hot issues.
This annual integrative pharmacology review analyzed the different growth rates and progress of traditional medicine in different diseases, which is able to provide a comprehensive description of the hot spot and development.
A number of researches concerning pharmacology of traditional medicine and active natural products over the past 12 months have outlined the importance of reviewing the progress. This annual integrative pharmacology review evaluates researches published during 2018 in different diseases including cardiovascular and cerebrovascular diseases, cancers, diabetes and metabolic diseases, and so on. The emphasis is on bioactive compounds and extracts from traditional herbs, as well as the novel molecular targets and mechanisms. Moreover, some traditional prescriptions in China and other geographical locations have also been included.
Mental disorders are considerate "the evil of the century" by renowned researchers, because a large part of the population in many countries is a diagnosticated, and currently affect youth and children. Among the numerous therapeutic interventions, the music therapy is a non-invasive approach. However, there are very few people who are professionally engaged in research and studies on the subject. Therefore, this article is a literature to talk about the benefits of music therapy sessions for people with stress, depression and anxiety disorders.
This retrospective cohort study showed that long-term traditional Chinese medicine as an adjuvant therapy can improve disease-free survival of postoperative lung cancer patients, especially in patients with stage I and II disease.
This study provided sufficient evidence that long-term traditional Chinese medicine treatment is associated with 5-year disease-free survival in postoperative lung cancer patients, especially in patients with stage I and II disease.
Objective: Traditional Chinese medicine (TCM) has been extensively used as one of popular alternative therapies for several cancers. However, it remains unclear whether TCM treatment is associated with longer survival in lung cancer patients. In this study, we explored the effect of long-term TCM treatment on patients with different stages of lung cancer. Methods: All information of lung cancer patients with stage I-III disease from January 2007 to September 2015 was collected for this retrospective cohort study. Those who were treated with TCM after surgery were divided into TCM group and the others were into the non-TCM group (control group). All patients were regularly followed up by clinic appointment or phone, and all survival data were collected from databases after the last follow-up in October 2017. Results: A total of 575 patients were included in this study, with 299 patients in the TCM group and 276 in the control group. For all patients, 5-year disease-free survival (DFS) was 62.2% in TCM group and 42.1% in the control group, and 6-year DFSs were 51.8% and 35.4%, respectively (HR = 0.51, 95% CI: 0.40 to 0.66, log-rank P ≤ 0.001). For patients with stage I, 5-year DFSs were 83.7% (TCM group) and 57.5% (control group) and 6-year DFSs were 73.7% and 51.9%, respectively (HR = 0.30, 95% CI: 0.18 to 0.50, log-rank P ≤ 0.001). For patients with stage II in the TCM group and the control group, 5-year DFSs were 59.4% and 17.6% and 6-year DFSs were 44.7% and 17.6%, respectively (HR = 0.31, 95% CI: 0.19 to 0.52, log-rank P ≤ 0.001), and for patients with stage III, 5-year and 6-year DFSs in the TCM group were 18.7% and 12.5% compared with 28.4% and 20.3% in the control group (HR = 1.06, 95% CI: 0.72 to 1.56, log-rank P = 0.76). Conclusions: This study demonstrated that long-term TCM treatment as an adjuvant therapy is able to improve the DFS of postoperative stage I-III lung cancer patients, especially in patients with stage I and II disease. However, these observational findings need being validated by large sample randomized controlled trials.
Regional ethnic medicine (REM) and traditional Chinese medicine (TCM) have unique experience in the treatment of cancer pain.
There are many different aspects of the treatment of cancer pain in REM and TCM.
TCM and REM are important cancer-assisted treatments in China. Especially for the treatment of cancer pain, TCM and REM are important alternatives.
REM and TCMare both important parts of traditional medicine in China, and they have their own characteristics in the understanding and prevention of diseases. This article compares the understanding, the theoretical prevention and treatment guidance and the clinical application of the REM and TCMon the cancer pain.
This review provides evidences for the recommendation of acupuncture preconditioning at Neiguan (PC6) point in coronary heart disease patients as a non-pharmacological therapeutic method to activate the miR-214/NCX1 pathway.
The concept of acupuncture preconditioning is described in the ancient book of Fan Wang Fang (Eastern Jin Dynasty of China). It refers to the application of acupuncture before the occurrence of disease or when the disease is relatively mild. According to the record of the ancient book of Huang Di Nei Jing (Qin Han Period of China, 475 B.C.-221 B.C.), acupuncture at Neiguan (PC6) point can prevent and treat angina pectoris in coronary heart disease (CHD). The WHO also recommends acupuncture as one of the alternative and complementary therapies for the prevention and treatment of angina pectoris in CHD.
Early reperfusion of ischemic cardiac tissue is usually the best option to improve clinical outcome of angina pectoris, especially of acute myocardial infarction. However, myocardial reperfusion may cause an abnormal increase of intracellular Ca2+-mediated cardiomyocyte death and consequent loss of cardiac function, which is referred to myocardial ischemia/reperfusion (I/R) injury. Recently, the microRNA-214 (miR-214)/Na+/Ca2+ exchanger (NCX) 1 co-expression is a key factor in cellular protection against myocardial apoptosis for myocardial I/R injury. Once activated, miR-214/NCX1 axis can inhibit several Ca2+ downstream signaling effectors that mediate cell death simultaneously. Studies have shown that acupuncture preconditioning has a protective effect on myocardial I/R injury, but its mechanism deserves further research. It has been proved that acupuncture preconditioning for ischemic myocardium successfully inhibit multiple Ca2+ handling related microRNAs that mediate cell death pathways, and miR-214 is one of its targets. In terms of clinical practice, coronary heart disease (CHD) patients benefit a lot from this intervention. However, there is barely no study correlating acupuncture preconditioning to the miR-214/NCX1 co-expression in patients with CHD. This review aims to discuss whether there is some evidence to justify a recommendation of acupuncture preconditioning in CHD patients as a non-pharmacological therapeutic method to activate the miR-214/NCX1 co-expression network model.
This review introduced the current major anti-inflammatory natural active molecules based on their chemical structures, and discussed their pharmacological mechanisms.
Natural active molecules are key sources of modern innovative drugs. Particularly, a great amount of natural active molecules have been reported to possess promising therapeutic effects on inflammatory diseases, including asthma, rheumatoid arthritis, hepatitis, enteritis, metabolic disorders and neurodegenerative diseases. However, these natural active molecules with various molecular structures usually exert anti-inflammatory effects through diversiform pharmacological mechanisms, which is necessary to be summarized systematically. In this review, we introduced the current major anti-inflammatory natural active molecules based on their chemical structures, and discussed their pharmacological mechanisms including anti-inflammatory molecular signaling pathways and potential target proteins, which providing a referential significance on the development of novel anti-inflammatory drugs, and also revealing new therapeutic strategies for inflammatory diseases.
Copyright © TMR Publishing Group.